Browse > Article

Results of a Ivor-Lewis Operation for Esophageal Squamous Cell Carcinoma  

Cho, Seong-Ho (Department of Thoracic and Cardiovascular Surgery, Kosin University College of Medicine)
Kim, Jong-In (Department of Thoracic and Cardiovascular Surgery, Kosin University College of Medicine)
Cho, Sung-Rae (Department of Thoracic and Cardiovascular Surgery, Kosin University College of Medicine)
Publication Information
Journal of Chest Surgery / v.40, no.12, 2007 , pp. 843-850 More about this Journal
Abstract
Background: The Ivor-Lewis operation has been widely applied for treating thoracic esophageal cancer, but more acceptable results from three-field lymph node dissection have recently been reported. In this study the efficacy of the Ivor-Lewis operation was evaluated. Material and Method: Among the 273 patients, who underwent operation for esophageal cancer between September 1994 and August 2004, we retrospectively studied 172 patients with esophageal squamous cell carcinoma and who had no other primary cancer and who underwent complete resection with an Ivor-Lewis operation. The postoperative complications, the short and long-term survival and the recurrence patterns were analyzed. Result: The postoperative staging was as follows: stage I in 40 cases, IIA in 48 cases, IIB in 18 cases, III in 55 cases, IVA in 5 cases and IVB in 6 cases. The operative mortality rate was 4% (7 of 172 pts). Postoperative complication occurred in 32 patients (18%) and tumor recurred in 55 patients (32%). The overall 5-year survival rate was 48%; it was 85.6% in stage I patients, 47.6% in IIA patients, 65% in IIB patients, 22.8% in III patients and 0% for those in IV (p<0.05). The 5-year survival rate according to the location of esophageal cancer was 26.5% for patients with tumor in the upper 1/3 of the esophagus and 52.4% for patients with tumor in the mid and lower 1/3 (p>0.05). Conclusion: The Ivor-Lewis operation is an acceptable surgical procedure for thoracic esophageal squamous cell carcinoma. Yet it is necessary to consider other surgical procedures, and especially three-field lymph node dissection for treating upper 1/3 esophageal cancer.
Keywords
Esophageal surgery; Esophageal neoplasms;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Law SYK, Fok M, Wong J. Pattern of recurrence after oesophageal resection for cancer: clinical implication. Br J Surg 1996;83:107-11   DOI   ScienceOn
2 Yim SB, Park JH, Baik HJ. Long term result of surgical treatment for esophageal cancer. Korean J Thorac Cardiovasc Surg 2001;34:148-55
3 O'Pourke I, Tait N, Mull C, Gebski V, Holland M, Johnson DC. Oesophageal cancer: Outcome of modern surgical management. Aust N Z J Surg 1995;65:11-6   DOI   PUBMED
4 Mitsuo T, Shoichi K, Hiroshi Y, Muneaski S, Yasuhito T. Clinical outcomes of extended esophagectomy with threefield lymph node dissection for esophageal squamous cell carcinoma. Am J Surg 2005;189:98-109   DOI   ScienceOn
5 Lee JH, Lee JC. Pulmonary complication after surgery for esophageal cancer. Korean J Thorac Cardiovasc Surg 2006;39:134-9   과학기술학회마을
6 Fergueson MK, Durkin AE. Preoperative prediction of the risk of pulmonary complication after esophagectomy for cancer. J Thorac Cardiovasc Surg 2002;123:661-9   DOI   ScienceOn
7 Kim YT, Sung SW, Kim JH. Long term survival after the resection of esophageal cancer. Korean J Thorac Cardiovasc Surg 1999;32:653-9
8 Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:364-72   DOI   PUBMED   ScienceOn
9 Masahiko T, Yoshiaki K, Haruchi U, Hiroshi A. Outcomes of extended lymph node dissection for squamous cell carcinoma of the thoracic esophagus. Ann Thorac Cardiovasc Surg 2001;7:325-9   PUBMED
10 Shin HJ, Kim CW, Park SI, Kim YH, Kim DK, Park SI. Anastomotic leakage and stricture relating to anastomotic level and methods in esophageal resection and reconstruction for esophageal cancer. Korean J Thorac Cardiovasc Surg 2006;39:208-13   과학기술학회마을
11 Bains MS, Stojadinovic A, Minsky B. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorc Cardiovasc Surg 2002;124:270-7   DOI   ScienceOn
12 Muller JM, Erasmi H, Stelzner M. Surgical therapy of oesophageal carcinoma. Br J Surg 1990;77:845-57   DOI   ScienceOn
13 King RM, Pairolero PC, Trastek VF, Payne WS, Bernatz PE. Ivor Lewis esophagectomy for carcinoma of the esophagus: early and late functional results. Ann Thorac Surgery 1987;44:119-22   DOI   ScienceOn
14 Fujita H, Kakegawa T. Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer: a comparision for three-field lymphadenectomy with 2-field lymphadenectomy. Ann Surg 1995;222:654-62   DOI   PUBMED   ScienceOn
15 Sato N, Koeda K, Ikeda K, et al. Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer. Ann Surg 2002;236:184-90   DOI   ScienceOn
16 Orringer MB. Transhiatal esophagectomy without thoracostomy for carcinoma of the thoracic esophagus. Ann Surg 1984;200:282-7   DOI   PUBMED   ScienceOn
17 Wenz F, Mamon H. Perioperative radiotherapy for cancer of the esophagus. Semin Surg Oncol 2001;20:33-9   DOI   ScienceOn
18 Visbal AL, Allen MS, Miller DL, Trastek VF, Pairolero PC. Ivor Lewis esophagogastrectomy for esophageal cancer. Ann Thorac Surg 2001;71:1803-8   DOI   ScienceOn